Our top pick for
BioTelemetry, Inc is a diagnostics & research business based in the US. BioTelemetry shares (BEAT) are listed on the NASDAQ and all prices are listed in US Dollars. BioTelemetry employs 1,700 staff and has a trailing 12-month revenue of around USD$414.8 million.
Since the stock market crash in March caused by coronavirus, BioTelemetry's share price has had significant negative movement.
Its last market close was USD$48.3, which is 7.35% down on its pre-crash value of USD$52.13 and 76.60% up on the lowest point reached during the March crash when the shares fell as low as USD$27.35.
If you had bought USD$1,000 worth of BioTelemetry shares at the start of February 2020, those shares would have been worth USD$614.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$977.11.
|Latest market close||USD$48.3|
|52-week range||USD$27.35 - USD$56|
|50-day moving average||USD$45.9603|
|200-day moving average||USD$44.0565|
|Wall St. target price||USD$54.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.48|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-7.91%|
|1 month (2020-10-30)||13.43%|
|3 months (2020-08-28)||21.08%|
|6 months (2020-05-29)||2.37%|
|1 year (2019-11-29)||4.30%|
|2 years (2018-11-30)||-31.91%|
|3 years (2017-11-30)||66.55%|
|5 years (2015-11-30)||283.03%|
Valuing BioTelemetry stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioTelemetry's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioTelemetry's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 115x. In other words, BioTelemetry shares trade at around 115x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
BioTelemetry's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioTelemetry's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioTelemetry's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$98.6 million.
The EBITDA is a measure of a BioTelemetry's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$414.8 million|
|Operating margin TTM||12.84%|
|Gross profit TTM||USD$252.5 million|
|Return on assets TTM||4.71%|
|Return on equity TTM||4.67%|
|Market capitalisation||USD$1.9 billion|
TTM: trailing 12 months
There are currently 3.6 million BioTelemetry shares held short by investors – that's known as BioTelemetry's "short interest". This figure is 7.8% down from 3.9 million last month.
There are a few different ways that this level of interest in shorting BioTelemetry shares can be evaluated.
BioTelemetry's "short interest ratio" (SIR) is the quantity of BioTelemetry shares currently shorted divided by the average quantity of BioTelemetry shares traded daily (recently around 268204.75830816). BioTelemetry's SIR currently stands at 13.24. In other words for every 100,000 BioTelemetry shares traded daily on the market, roughly 13240 shares are currently held short.
However BioTelemetry's short interest can also be evaluated against the total number of BioTelemetry shares, or, against the total number of tradable BioTelemetry shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioTelemetry's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 BioTelemetry shares in existence, roughly 100 shares are currently held short) or 0.165% of the tradable shares (for every 100,000 tradable BioTelemetry shares, roughly 165 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BioTelemetry.
Find out more about how you can short BioTelemetry stock.
We're not expecting BioTelemetry to pay a dividend over the next 12 months.
Over the last 12 months, BioTelemetry's shares have ranged in value from as little as $27.35 up to $56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioTelemetry's is 1.186. This would suggest that BioTelemetry's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.